Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,174.80
(
1.94%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
92.79
(
-2.81%
)
Bitcoin
74,385.94
(
0.25%
)
News Focus
News Focus
Post# of 23979
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

kei

Send PM Follow Ignore
Followers 305
Posts 22916
Boards Moderated 0
Alias Born 10/10/2007

kei

Re: None

Tuesday, 12/15/2015 7:13:09 AM

Tuesday, December 15, 2015 7:13:09 AM

Post# of 23979
KTOV - Kitov Pharmaceuticals' Pivotal Phase III Trial Successfully Meets Primary Efficacy Endpoint
http://finance.yahoo.com/news/kitov-pharmaceuticals-pivotal-phase-iii-120000858.html
- Company plans to file for marketing approval in 2016 for its combination drug KIT-302
- Data show KIT-302 is more effective at lowering hypertension than amlodipine besylate alone
- KIT-302 would become the first single medication to treat both osteoarthritis pain and hypertension
- KIT-302 addresses a multi-billion market

°°° (\__/) (\_(\ ° ° °
°°° (='.'=) (=' :') °°°
°°° (")_(") (,(')(')°°°
°°° °°° °°° °°° °°°


Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today